Board Member
Sutro Biopharma, Inc. (STRO)Equibles does not estimate personal net worth.
Get an email with a short summary when Sutro Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get STRO alertsJane Chung is recorded as COO at Sutro Biopharma, Inc. (STRO) since December 1, 2023 and CEO and Board Member at Sutro Biopharma, Inc. (STRO). The newest filing on record that lists Jane Chung as CEO and Board Member at Sutro Biopharma, Inc. (STRO) is dated April 22, 2026. Sutro Biopharma, Inc. reported in an 8-K filed March 13, 2025 that Jane Chung was appointed Chief Executive Officer, effective March 13, 2025. Sutro Biopharma, Inc. reported in an 8-K filed March 13, 2025 that Jane Chung was appointed Class II Director, effective March 13, 2025. Sutro Biopharma, Inc. reported in an 8-K filed November 21, 2023 that Jane Chung was appointed President and Chief Operating Officer, effective December 1, 2023. The proxy statement of Sutro Biopharma, Inc. reports total compensation of $1,575,930 for Jane Chung in fiscal 2025, including a base salary of $652,000. Disclosed compensation is on record for 2 fiscal years. Jane Chung has spoken on 1 investor event across 1 company, most recently for Sutro Biopharma, Inc. on June 5, 2026. Sutro Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Sutro Biopharma, Inc. includes Gregory Chow (CFO), Gregory K. Chow (CFO), David Pauling (General Counsel) and 4 others.
“Effective as of the Newell Separation Date, the Board appointed Jane Chung, the Company's President and Chief Operating Officer, to succeed Mr. Newell as Chief Executive Officer.”
“The Board also appointed Ms. Chung as a Class II Director of the Company, effective as of the Newell Separation Date.”
“I became the CEO in March of last year with our strategic pivot when we committed to delivering three INDs or programs into the clinic in three years. We're now on track and accelerating to I would like to first introduce the following members of the Board of Directors who are with us this morning.”
2023-12-01–present
Start not stated–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 22, 2026
Proxy statement
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member, COO
2023-12-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Sutro Biopharma, Inc. (STRO) | R.Ph. Chief Executive Officer | $652,000 | $1,575,930 |
| 2024 | Sutro Biopharma, Inc. (STRO) | R.Ph. Chief Executive Officer | $560,000 | $1,443,360 |
